Khondrion
Concept and comm.
An important message
Communicative support for Khondrion
Research institute Khondrion in Nijmegen is pioneering the development of a drug to treat energy metabolism diseases. There is now increasing hope for many sick children and their parents. With the theme 'Bringing Energy to life', Capital Advertising supports the research of Prof Dr Jan Smeitink and his team. For more information, visit www.khondrion.com.
About Khondrion
Khondrion is a clinical-stage biomedical company that discovers and develops therapies for primary mitochondrial diseases. Based on proprietary scientific research and a deep understanding of mitochondria in health and disease, the company is advancing its lead drug candidate sonlicromanol.
Sonlicromanol and other compounds from Khondrion's proprietary programme have the potential to be developed as drugs for other diseases and conditions affecting normal mitochondrial function. Khondrion is advancing preclinical research and development in several promising areas to accelerate the discovery and development of potential drugs for mitochondrial diseases. To this end, Khondrion collaborates with patient organisations worldwide, as well as its global clinical and academic network.